Haemonetics Debt 2024

Haemonetics Aktienanalyse

What does Haemonetics do?

Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Haemonetics's Debt Structure

Haemonetics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Haemonetics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Haemonetics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Haemonetics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Haemonetics stock

What is the debt of Haemonetics this year?

Haemonetics has a debt level of 628.99 USD this year.

What was the debt of Haemonetics compared to the previous year?

The debt of Haemonetics has increased by 22.35% compared to the previous year increased.

What are the consequences of high debt for investors in Haemonetics?

High debt can pose a risk for investors of Haemonetics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Haemonetics?

Low debt means that Haemonetics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Haemonetics affect the company?

An increase in debt of Haemonetics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Haemonetics affect the company?

A reduction in debt of Haemonetics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Haemonetics?

Some factors that can influence the debt of Haemonetics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Haemonetics so important for investors?

The debts of Haemonetics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Haemonetics take to change the debt?

To change the debt, Haemonetics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Haemonetics pay?

Over the past 12 months, Haemonetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Haemonetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Haemonetics?

The current dividend yield of Haemonetics is .

When does Haemonetics pay dividends?

Haemonetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Haemonetics?

Haemonetics paid dividends every year for the past 0 years.

What is the dividend of Haemonetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Haemonetics located?

Haemonetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Haemonetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Haemonetics from 8/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/10/2024.

When did Haemonetics pay the last dividend?

The last dividend was paid out on 8/10/2024.

What was the dividend of Haemonetics in the year 2023?

In the year 2023, Haemonetics distributed 0 USD as dividends.

In which currency does Haemonetics pay out the dividend?

The dividends of Haemonetics are distributed in USD.